Protocol Ledger

NCT05973773 · Phase III · ACTIVE NOT RECRUITING

REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)

Interventional Phase III clinical trial protocol NCT05973773 sponsored by Taiho Oncology in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-12-18 Enrollment: 285 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05973773
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)285 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05973773
Protocol FieldVerified Registry Value
NCT IdentifierNCT05973773
Consolidated Lead SponsorTaiho Oncology
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment285 participants (ACTUAL)
Registered Start Date2023-12-18
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05973773
Hospital Research SiteLocationSite Profile
Comprehensive Cancer Centers of Nevada - HendersonHenderson, NVOpen Hospital Dossier ->
Comprehensive Cancer Centers of Nevada - NorthwestLas Vegas, NVOpen Hospital Dossier ->
MD Anderson Cancer CenterHouston, TXOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI